Home » Science and Research » MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy

MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy

August 15, 2019 Science Daily Off Science and Research

A study has identified a possible second-line treatment for melanoma patients.
Read Original Article: MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy »

Share on Facebook

Pin on Pinterest

Tweet about this on Twitter

Share on LinkedIn

Share on Reddit

Share on Tumblr

About The Author

Science Daily